Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields + Chemotherapy in Gastric/GEJ Cancer
NCT04281576Completed
- Sponsor
- NovoCure
- Start
- Dec 2019
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by NovoCure. Primary endpoint: Objective Response Rate at 2 years. Started Dec 2019; status: completed.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04281576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281576.